NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended June 30, 2008. The company incurred a net loss attributable to common stockholders of $12.2 million, or $0.19 per share, basic and diluted, for the second quarter of 2008, compared with a net loss attributable to common stockholders in the second quarter of 2007 of $10.1 million, or $0.22 per share, basic and diluted. For the six months ended June 30, 2008, Antigenics incurred a net loss attributable to common stockholders of $23.4 million, or $0.39 per share, basic and diluted, compared with a net loss attributable to common stockholders of $18.9 million, or $0.41 per share, basic and diluted, for the comparable period in 2007.
